News

FDA approves Galderma’s Mirvaso for redness of rosacea

BY Alaric DeArment

FORT WORTH, Texas — The Food and Drug Administration has approved a drug made by Galderma Labs for treating a side effect of rosacea in adults, the company said.

Galderma announced the approval of Mirvaso (brimonidine) topical gel in the 0.33% strength for the topical treatment of facial erythema of rosacea. The drug is applied once per day to reduce redness and lasts up to 12 hours. The company expects the drug to become available in pharmacies next month.

"Facial redness is the most common symptom of rosacea, but until now, physicians have been without prescription treatment options to specifically address this patient need," University of Louisville medical professor and lead investigator in the late-stage clinical trials of the drug Mark Jackson said. "The FDA approval of Mirvaso marks a turning point in rosacea treatment: We are now able to provide patients who deal with the daily frustrations caused by the redness of rosacea with an effective therapy."

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

McKesson Specialty Health names new chief medical officer

BY Michael Johnsen

THE WOODLANDS, Texas — McKesson Specialty Health and The US Oncology Network on Wednesday announced the appointment of Michael Seiden as chief medical officer, effective Sept, 22. 

"Dr. Seiden’s distinguished track record and extensive experience across patient care, research and operations makes him uniquely qualified to lead our organization’s clinical and physician engagement strategy," stated Marc Owen, president, McKesson Specialty Health. "His experience as a practicing oncologist and in running a major cancer center will complement the existing leadership team and ensure that a physician’s perspective is contemplated in all decisions."

In his new capacity, Seiden will lead McKesson Specialty Health’s clinical strategy and work closely with physicians in The US Oncology Network and other community practices across the country to enhance the delivery of high-quality, evidence-based care.

"Dr. Seiden’s expertise will be beneficial in driving The US Oncology Network’s vision of improving patient outcomes and quality of life," added Steven Paulson, president and chairman of the board for Texas Oncology, a practice affiliated with The US Oncology Network. "Physicians from The US Oncology Network participated in the candidate search which led to Dr. Seiden’s appointment, and we are pleased to welcome him to the organization."

Until recently, Seiden served as the CEO and president of Fox Chase Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center research facility and hospital in Philadelphia. Under his leadership, Fox Chase merged with Temple University Health system in 2012. Prior to Fox Chase, Seiden spent many years practicing at Massachusetts General Hospital, where he served as chief of the Clinical Research Unit, Cancer Science Division. A nationally known expert on ovarian cancer, Seiden has been a practicing oncologist for more than 20 years.

Seiden received his bachelor’s degree from Oberlin College and his medical and Ph.D. degrees from Washington University. He completed his residency at Massachusetts General Hospital, his fellowships in medical oncology and bone marrow transplant at Dana Farber Cancer Institute, and his post-doctoral fellowship at Brigham and Women’s Hospital, Department of Pathology.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

Reports: Fruth to sell tamper-resistant pseudoephedrine drug to combat meth

BY Alaric DeArment

NEW YORK — Fruth Pharmacy is taking up a pseudoephedrine product for nasal congestion designed to deter the manufacturing of methamphetamine at all of its stores, according to published reports.

The West Virginia MetroNews Network reported that Fruth — which operates 25 stores in West Virginia and Ohio — would start selling Acura Pharmaceuticals’ Nexafed at its stores.

Currently, Nexafed is available only in 30-mg pills, and Fruth will continue to sell Johnson & Johnson’s Sudafed in other strengths until other strengths of Nexafed become available, and Sudafed will be phased out.

Nexafed, which Acura describes as a "next-generation" pseudoephedrine product, has tamper-resistant properties that disrupt the extraction of pseudophedrine from the pill and its conversion to methamphetamine. It will still have the same restrictions on purchasing as Sudafed and other pseudoephedrine products, according to MetroNews.

According to Charleston, W.Va., ABC affiliate WCHS, more than 300 meth labs have been uncovered in West Virginia so far this year, with more than one-third of them in Kanawha county alone.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES